Table 2 Baseline features of patients across primary and secondary MN
From: A cohort study of membranous nephropathy, primary or secondary
| Primary MN | Secondary MN | p value | ||
|---|---|---|---|---|
| Disease stage | Mild | 16 (20.3%) | 3 (10.3%) | |
| Moderate | 60 (75.9%) | 20 (69%) | 0.014 | |
| Severe | 3 (3.8%) | 6 (20.7%) | ||
| Gender | Male | 50 (63.3%) | 16 (55.2%) | 0.44 |
| HTN | Positive | 51 ((64.6%) | 17 (58.6%) | 0.57 |
| Diabetes | Positive | 9 (11.4%) | 2 (6.9%) | 0.49 |
| ACEi/ARB administration | Positive | 68 (86.1%) | 23 (79.3%) | 0.39 |
| Immunosuppressive treatment | PDN + CNI | 48 (60.8%) | 13 (44.8%) | |
| PDN + CNI + MMF | 4 (5.1%) | 5 (17.2%) | ||
| Rituximab | 2 (2.5%) | - | ||
| Ponticelli regimen | 8 (10.1%) | 2 (6.9%) | ||
| PDN | 5 (6.3%) | 2 (6.9%) | ||
| None | 9 (11.4%) | 5 (17.2%) |